Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.52 |
| ▸ | AURKA | O14965 | 9/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28021613 | 0.93 | HRH4 (0.44) | HRH4AURKAFLT3HTR6KDR | |
| SCHEMBL28553029 | 0.91 | PIK3CB (0.47) | HRH4AURKAAURKB | |
| SCHEMBL28021594 | 0.91 | HRH4 (0.48) | HRH4AURKAFLT3HRH3FLT1 | |
| SCHEMBL28565380 | 0.84 | HRH4 (0.51) | HRH4AURKAAURKBEGFRNTRK1 | |
| SCHEMBL2203952 | 0.81 | AURKA (0.57) | HRH4AURKAHRH3HTR6AURKB | |
| SCHEMBL28022122 | 0.81 | AURKA (0.46) | AURKAFLT3FLT1KDRAURKB | |
| SCHEMBL28562522 | 0.79 | AURKA (0.41) | AURKAAURKB | |
| SCHEMBL28562221 | 0.75 | AURKA (0.41) | AURKA | |
| SCHEMBL28556719 | 0.75 | AURKA (0.42) | AURKA | |
| SCHEMBL2203821 | 0.73 | AURKA (0.64) | HRH4AURKAFLT3FLT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| CN-104797267-A | Method of treating tyrosine kinase inhibitor-resistant malignancies in patients with genetic polymorphism or AHI1 dysregulation or mutation using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof | DEL MAR PHARMACEUTICALS | 2015-07-22 | — | — | CN | disclosed |